Table 1.

Baseline characteristics and cell collection yield of patients

SubjectAge, ySexNo. VOE in last 2 yNo. ACS in last 2 yHistory of splenectomyHistory of CNS eventResting CD34+*Plerixafor dose, μg/kgPeak CD34+, cells/μLPlerixafor to apheresis time, hCD34+ cells collected, ×106/kgIdeal predicted CD34+ yield, × 106/kgCD34+ postselection recovery (purity), %
30 No Yes 1,2 180 36 5:42 0.069 3.1 81, (32) 
19 No Yes 3,3 180 65 5:20 0.616 5.1 54, (84) 
26 No No 2,4 180 31 5:35 1.2 2.6 20, (68) 
25 Yes Yes 10,31 240 290 3:55 24.53 26.8 59, (99) 
38 Yes Yes 2,2 240 27 3:54 2.94 2.2 41, (94) 
25 Yes Yes 5,8 240 156 3:54 16.38 13.1 61, (99) 
SubjectAge, ySexNo. VOE in last 2 yNo. ACS in last 2 yHistory of splenectomyHistory of CNS eventResting CD34+*Plerixafor dose, μg/kgPeak CD34+, cells/μLPlerixafor to apheresis time, hCD34+ cells collected, ×106/kgIdeal predicted CD34+ yield, × 106/kgCD34+ postselection recovery (purity), %
30 No Yes 1,2 180 36 5:42 0.069 3.1 81, (32) 
19 No Yes 3,3 180 65 5:20 0.616 5.1 54, (84) 
26 No No 2,4 180 31 5:35 1.2 2.6 20, (68) 
25 Yes Yes 10,31 240 290 3:55 24.53 26.8 59, (99) 
38 Yes Yes 2,2 240 27 3:54 2.94 2.2 41, (94) 
25 Yes Yes 5,8 240 156 3:54 16.38 13.1 61, (99) 

ACS, acute chest syndrome; CNS, central nervous system; VOE, vaso-occlusive episode.

*

Multiple resting CD34+ counts were measured, all within 3 months before Plx. Lowest and highest are depicted here.

Predicted ideal collection yields were calculated; see also right half of Figure 1F.

Technical deviation from standard selection protocol.

Close Modal

or Create an Account

Close Modal
Close Modal